| Drug Type Contrast agent, Small molecule drug | 
| Synonyms MPB 2043, MPB2043 | 
| Target- | 
| Action enhancers | 
| Mechanism Magnetic resonance imaging enhancers | 
| Therapeutic Areas | 
| Active Indication | 
| Inactive Indication- | 
| Originator Organization | 
| Active Organization | 
| Inactive Organization- | 
| License Organization- | 
| Drug Highest PhasePhase 1 | 
| First Approval Date- | 
| Regulation- | 
| Indication | Highest Phase | Country/Location | Organization | Date | 
|---|---|---|---|---|
| Squamous Cell Carcinoma of Head and Neck | Phase 1 | Taiwan Province  | 19 Dec 2024 | |
| Lymphatic Metastasis | Phase 1 | United States  | 12 Oct 2022 | |
| Lymphatic Metastasis | Phase 1 | Taiwan Province  | 12 Oct 2022 | 





